Skip to main content
Equibles
WGS logo

WGS · GeneDx Holdings Corp.

Track WGS — free

Use WGS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about WGS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$86.85 -2.39 (-2.68%)
Russell 2000 member Rebalance outlook locked
Market Cap
$2.69B
Shares
29.82M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$89.24 Open$90.32 Day$88.55–91.78 52W close$34.51–167.52 Avg vol 30d733K Short int6.3M · 21.1% float · 6.4d Short vol50% Last earningsAug 3, 2026 DataMay 2023–Aug 2026 Filing10-Q · Aug 3

Raw chart and full-history price indicators begin at the captured split on May 4, 2023; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 2, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 3, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.5 · calm Equity put/call 0.39
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +3%
      above
      Price vs 50-day avg +28%
      above
      RSI (14) 69
      neutral
      MACD trend Positive
      52-week position 41%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +29%
      trailing
      6-month return +1%
      trailing
      YTD return −31%
      this year
      Relative strength −13%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $70 › 200d $86 — 200d above 50d
      Institutional flow Distributing
      -8% holders QoQ · +55 funds added
      Insider flow Accumulating
      Net +$10.0M over 90 days · 67% sells
      Short interest Rising
      21.09% of float · ▲ +7.5% MoM · 6.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      226 holders — mid 3-yr range
      Squeeze score 82
      high risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +40%
      Y/Y
      Gross margin 70%
      expanding
      EPS growth +62%
      Y/Y
      Free cash flow $14.3M
      Balance sheet $52.3M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 84%
      annualized · 1-yr
      Max drawdown −79%
      past year
      ATR 5.4%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 4 of last 4
      Latest guidance · from the 8-K filed Aug 3, 2026
      Full Year 2026
      Revenue Maintained $475M – $490M
      May 4, 2026 $475M – $490M changed to Aug 3, 2026 $475M – $490M
      prior FY $427.54M midpoint +12.9% Y/Y
      Exome and genome revenue Initiated at least 20%
      Adjusted gross margin Non-GAAP Maintained 70%
      May 4, 2026 70% changed to Aug 3, 2026 70%
      Third Quarter 2026
      Revenue Initiated $122M – $124M
      prior qtr $114.44M midpoint +7.5% QoQ
      Adjusted gross margin Non-GAAP Initiated 70%
      Exome and genome revenue Maintained $110M – $112M
      Jun 30, 2026 $110M – $112M changed to Aug 3, 2026 $110M – $112M
      Prior guidance period ended · from the 8-K filed May 4, 2026
      Growth in exome and genome revenue · Second Quarter of 2026 $100M
      Revenue · Second Quarter of 2026 $110M – $112M
      Adjusted gross margin · Second Quarter of 2026 70%
      Guided vs delivered · last 4 settled
      Revenue Second Quarter of 2026
      guided $110M – $112M
      $114.44M Beat +3.1%
      Revenue Full Year 2025
      guided $425M – $428M
      $427.54M In line
      Revenues full year 2024
      guided $235M – $245M
      $305.45M Beat +27.3%
      Full-year revenue from continuing operations full-year 2023
      guided $187M – $192M
      $202.57M Beat +6.9%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +3% Bullish
      Price vs 50-day avg
      +28% Bullish
      RSI (14)
      69 Neutral
      MACD trend
      Positive Bullish
      52-week position
      41% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $70 › 200d $86 — 200d above 50d
      Institutional flow Distributing
      -8% holders QoQ · +55 funds added
      Insider flow Accumulating
      Net +$10.0M over 90 days · 67% sells
      Short interest Rising
      21.09% of float · ▲ +7.5% MoM · 6.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      226 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $35 Now $89 · 41% Range high $168
      vs 200-day avg +3% vs 50-day avg +28%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      GAAP → non-GAAP reconciliation
      GAAP Net (loss) income -17.74M
      +6.71M Depreciation and amortization
      +6.34M Stock-based compensation
      +3.3M Restructuring costs
      -220K Change in FV of financial liabilities
      +2.02M Other
      = Adjusted net income 411K
      Pro forma cash on hand $188M Q2 2026 —
      Q2 ARR $3,250 Q2 2026 —
      Growth in exome and genome revenue 27% First Quarter 2026 —
      Q1 ARR $3,300 Q1 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Diagnostics & Research — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      WGS
      GeneDx Holdings Corp.
      this stock
      		$2.69B -31.4% +40.0% — 21.1%
      TMO
      Thermo Fisher Scientific Inc.
      		 $234.31B +8.8% +14.5% 34.1 1.3%
      DHR
      Danaher Corp /De/
      		 $151.51B -5.8% +8.5% 38.2 1.2%
      NTRA
      Natera, Inc.
      		 $48.82B +47.8% -2.8% — 3.0%
      A
      Agilent Technologies, Inc.
      		 $43.80B +15.9% +6.4% 31.1 1.8%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      226
      % held
      109.6%
      Net QoQ
      +827.5K sh
      Top holder
      Corvex Management LP
      Held Float
      View
      Held by Funds
      Fund positions
      239
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      6.3M
      Days to cover
      6.4d
      Change
      +440.7K sh
      View
      Short Volume
      Short vol %
      50%
      As of
      Aug 27, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      19
      Value
      $1.2K
      As of
      Jul 23, 2026
      View
      Off-Exchange
      Off-exchange %
      42.5%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$10.0M
      Buyers / Sellers
      1 / 2
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $427.5M
      Net income (FY)
      $-21.0M
      EPS diluted
      $-0.73
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Aug 11, 2026
      This year
      15
      View
      Proposed Sales
      Value
      $929.9K
      Shares
      9.4K
      Filed
      Feb 2, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Sep 8, 2026
      Last call
      Aug 11, 2026
      View
      Investor Relations
      Upcoming events
      1
      View

      Performance

      Raw-price comparisons begin at the captured split on May 4, 2023; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      WGS +8.1% +29.4% +1.3% +37.1% -31.4%
      SPY +1.1% +4.0% +14.7% +3.2% +13.1%
      vs SPY +7.0% +25.4% -13.4% +33.8% -44.5%
      Key facts CIK 1818331 CUSIP 81663L200 13F (30d) 201 filings 199 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)